LSE - Delayed Quote USD
Editas Medicine, Inc. (0IFK.L)
1.6900
+0.0800
+(4.97%)
At close: May 2 at 7:08:05 PM GMT+1
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Gilmore O'Neill M.D. | President, CEO & Director | 1.12M | -- | 1964 |
| Dr. Feng Zhang Ph.D. | Co-Founder & Scientific Advisory Board Member | -- | -- | -- |
| Dr. George McDonald Church Ph.D. | Co-Founder & Scientific Advisory Board Member | -- | -- | 1954 |
| Ms. Amy Parison | Senior VP & CFO | -- | -- | 1986 |
| Mr. Gregory Whitehead | Executive VP and Chief Technical & Quality Officer | -- | -- | -- |
| Dr. Linda C. Burkly Ph.D. | Executive VP & Chief Scientific Officer | 522.44k | -- | 1958 |
| Ms. Linea Aspesi | Executive VP & Chief Administration Officer | -- | -- | 1970 |
| Cristi Barnett | Senior VP of Corporate Communications & Investor Relations | -- | -- | -- |
| Mr. Damien Grierson J.D. | Senior VP, General Counsel & Corporate Secretary | -- | -- | -- |
| Mr. Frank Panaccio | Senior VP & Chief Business Officer | -- | -- | -- |
Editas Medicine, Inc.
- Full Time Employees:
- 246
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Corporate Governance
Editas Medicine, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 6, 2025 at 12:30 PM UTC - May 12, 2025 at 12:30 PM UTC
Editas Medicine, Inc. Earnings Date
Recent Events
Recent Events Information Not Available